TRCT
ADMA icon

Tower Research Capital (TRC)’s ADMA Biologics ADMA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1K Sell
10,643
-11,246
-51% -$103K ﹤0.01% 2282
2026
Q1 		$197K Buy
21,889
+10,910
+99% +$172K 0.01% 1630
2025
Q4 		$200K Sell
10,979
-1,204
-10% -$20.3K ﹤0.01% 1435
2025
Q3 		$179K Sell
12,183
-5,846
-32% -$100K ﹤0.01% 1561
2025
Q2 		$328K Buy
18,029
+13,278
+279% +$271K 0.01% 1341
2025
Q1 		$94.3K Sell
4,751
-34,485
-88% -$596K ﹤0.01% 1805
2024
Q4 		$673K Buy
39,236
+35,763
+1,030% +$673K 0.01% 871
2024
Q3 		$69.4K Sell
3,473
-34,307
-91% -$533K ﹤0.01% 2525
2024
Q2 		$422K Buy
37,780
+35,813
+1,821% +$300K 0.01% 1474
2024
Q1 		$13K Sell
1,967
-27,567
-93% -$151K ﹤0.01% 3427
2023
Q4 		$133K Buy
29,534
+20,632
+232% +$76.3K ﹤0.01% 2413
2023
Q3 		$31.9K Sell
8,902
-10,131
-53% -$39K ﹤0.01% 2973
2023
Q2 		$70.2K Sell
19,033
-502
-3% -$1.86K ﹤0.01% 2305
2023
Q1 		$64K Buy
19,535
+10,712
+121% +$37K ﹤0.01% 2275
2022
Q4 		$34K Sell
8,823
-14,574
-62% -$45K ﹤0.01% 2626
2022
Q3 		$57K Sell
23,397
-12,636
-35% -$30.3K ﹤0.01% 3032
2022
Q2 		$71K Buy
36,033
+17,971
+99% +$35.4K ﹤0.01% 2563
2022
Q1 		$33K Buy
18,062
+11,496
+175% +$17.9K ﹤0.01% 3052
2021
Q4 		$9K Buy
+6,566
New +$8.63K ﹤0.01% 4665
2021
Q3 		– Sell
-533
Closed -$1K – 5723
2021
Q2 		$1K Sell
533
-25,387
-98% -$44.7K ﹤0.01% 5163
2021
Q1 		$46K Buy
25,920
+7,527
+41% +$17.2K ﹤0.01% 3186
2020
Q4 		$35K Sell
18,393
-51,455
-74% -$108K ﹤0.01% 3442
2020
Q3 		$167K Buy
69,848
+55,308
+380% +$152K ﹤0.01% 2733
2020
Q2 		$43K Buy
+14,540
New +$41.8K ﹤0.01% 3150
2020
Q1 		– Sell
-8,506
Closed -$34K – 2963
2019
Q4 		$34K Buy
8,506
+1,160
+16% +$5.06K ﹤0.01% 1573
2019
Q3 		$32K Sell
7,346
-6,022
-45% -$25.2K ﹤0.01% 2128
2019
Q2 		$52K Buy
13,368
+13,268
+13,268% +$58.6K ﹤0.01% 1545
2019
Q1 		$0 Sell
100
-4,017
-98% -$14.2K ﹤0.01% 3730
2018
Q4 		$10K Buy
4,117
+4,092
+16,368% +$20.3K ﹤0.01% 2443
2018
Q3 		$0 Buy
+25
New +$144 ﹤0.01% 3706
2017
Q4 		– Sell
-11,673
Closed -$36K – 3454
2017
Q3 		$36K Buy
11,673
+10,532
+923% +$35.1K ﹤0.01% 2260
2017
Q2 		$4K Buy
1,141
+375
+49% +$1.51K ﹤0.01% 2064
2017
Q1 		$4K Sell
766
-19
-2% -$94 ﹤0.01% 2277
2016
Q4 		$4K Sell
785
-6
-0.8% -$34 ﹤0.01% 3120
2016
Q3 		$6K Sell
791
-611
-44% -$3.88K ﹤0.01% 2401
2016
Q2 		$9K Sell
1,402
-4,054
-74% -$28.4K ﹤0.01% 2900
2016
Q1 		$44K Buy
5,456
+5,022
+1,157% +$28.7K 0.01% 839
2015
Q4 		$4K Sell
434
-185
-30% -$1.67K ﹤0.01% 3138
2015
Q3 		$6K Buy
619
+116
+23% +$1.07K ﹤0.01% 2633
2015
Q2 		$5K Sell
503
-504
-50% -$4.36K ﹤0.01% 3215
2015
Q1 		$10K Buy
1,007
+807
+404% +$8.13K ﹤0.01% 2769
2014
Q4 		$2K Buy
+200
New +$2.29K ﹤0.01% 3298

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tower Research Capital (TRC)'s ADMA Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its ADMA Biologics (ADMA) stake by 51% in Q2 2026, selling an estimated $103K and leaving 10,643 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2282.

Tower Research Capital (TRC) first reported a position in ADMA in Q4 2014 and has held it in 42 quarters since. The position peaked at $673K in Q4 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Tower Research Capital (TRC) held 10,643 shares of ADMA Biologics worth $89.1K as of Q2 2026.
  • Tower Research Capital (TRC) sold 11,246 ADMA Biologics shares in Q2 2026, an estimated $103K.
  • ADMA Biologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2282 holding.
  • Tower Research Capital (TRC) first reported a position in ADMA Biologics in Q4 2014 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s ADMA Biologics position peaked at $673K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.